Covidien and PETNET solutions enter an agreement for Nuclear Medicine Products

Covidien, a leading global provider of healthcare products, and PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. and a leader in radiopharmaceutical distribution, jointly announced they have entered into a co-marketing agreement to offer a combined portfolio of high energy and low energy radioisotopes to the nuclear medicine community in the United States.

Covidien, a leading global provider of healthcare products, and PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. and a leader in radiopharmaceutical distribution, jointly announced they have entered into a co-marketing agreement to offer a combined portfolio of high energy and low energy radioisotopes to the nuclear medicine community in the United States.

Covidien Imaging Solutions and PETNET will create a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents, or radiopharmaceuticals, designed to illuminate conditions, such as cancer or heart disease, during imaging procedures. The agreement brings together Covidien's single photo emission computed tomography (SPECT) products and PETNET's positron emission tomography (PET) products.

Steve Hanley, President, Imaging Solutions, Covidien said, This agreement further validates the efforts Covidien has undertaken in recent years to enhance our reputation as a valued supplier of essential diagnostic products. Hanley added With the agreement we are positioned to offer our nuclear medicine customers expanded access to both product lines to help them provide better patient diagnostic services. It also provides PETNET with access to our extensive SPECT product offerings.